Xenova Enters Potential $63M Deal With Genentech For OX40 April 24, 2002 By Nuala Moran LONDON - Xenova Group plc signed a deal worth up to US$63 million plus royalties with Genentech Inc. for rights to Xenova’s preclinical OX40 program in immune inflammatory diseases. (BioWorld International)Read More
